Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein

Newer Version Available: 6949-DR-100
A New rh TRAIL R1 is Now Available! ~2 fold better activity; CHO expressed; No his tag!
Formulations:
Catalog # Availability Size / Price Qty
347-DR-100
Product Details
Citations (5)
FAQs
Supplemental Products
Reviews

Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein Summary

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 1-3 ng/mL in the presence of 6 ng/mL of Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC).
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human TRAIL R1/TNFRSF10A protein
Human TRAIL R1
(Ala109 - Asn239) &
(Thr110 - Asn239)
Accession # AAC51226
IEGRMD Human IgG1
(Pro100 - Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Ala109 & Thr110
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
43 kDa (monomer)
SDS-PAGE
46 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

347-DR

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

347-DR/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TRAIL R1/TNFRSF10A

Human TRAIL R1 (TNF-related apoptosis inducing ligand receptor 1), also called DR4 (death receptor 4), is a 50 ‑ 57 kDa, 468 amino acid (aa) type 1 transmembrane protein in the TNF R family, designated TNFRSF10A (1 ‑ 3). Of the five receptors for TRAIL (also called APO2 ligand) in humans, TRAIL R1/DR4 and TRAIL R2/DR5 are apoptosis-inducing and share 59% aa identity within the cytoplasmic death domain (aa 365 ‑ 448 of human TRAIL R1) (1 ‑ 3). Rodents do not express TRAIL R1/DR4. Human decoy receptors TRAIL R3 and TRAIL R4 have non-functional death domains but share ~60% aa identity with TRAIL R1 within extracellular TNFR domains (aa 107 ‑ 229), while the secreted TRAIL receptor osteoprotegerin shares only 18% aa identity with TRAIL R1. Trimeric TRAIL engagement of TRAIL R1 induces apoptosis by recruiting a cytosolic death-inducing signaling complex (DISC) that includes the adaptor FADD and caspases 8 and 10 (2 ‑ 6). TRAIL R1 translational modifications, such as O-glycosylation and palmitoylation, promote apoptosis by enhancing oligomerization and presence in lipid rafts, respectively (3 ‑ 6). Recombinant human TRAIL R1 neutralizes the ability of TRAIL to induce apoptosis (1). TRAIL R1 protein is expressed mainly in damaged, infected and malignant cells and can be repressed by hedgehog proteins in oncogenic cells (3, 7, 8). TRAIL R1 is also expressed on hemopoietic cells and influences activities such as monocyte migration (9). On senescent neutrophils, CXCL12/SDF-1 engagement of CXCR4 induces expression of all TRAIL R (7). TRAIL functions in immune surveillance, inducing apoptosis in cancer cells but not normal cells (3, 10, 11). TRAIL R1 surface expression correlates more closely than that of TRAIL R2 with TRAIL induction of apoptosis on tumor cells such as melanoma and chronic lymphocytic and acute myeloid leukemias (6, 12, 13).

References
  1. Pan, G. et al. (1997) Science 276:111.
  2. Zauli, G. and P. Secchiero (2006) Cytokine Growth Factor Rev. 17:245.
  3. Yang, A. et al. (2010) Curr. Opin. Cell Biol. 22:837.
  4. Rossin, A. et al. (2009) Biohem. J. 419:185.
  5. Psahoulia, F.H. et al. (2007) Mol. Cancer Ther. 6:2591.
  6. Ries, C.R. et al. (2010) Cell Death Dis. 1:e83.
  7. Lum, J.J. et al. (2005) J. Immunol. 175:1232.
  8. Kurita, S. et al. (2010) Oncogene 29:4848.
  9. Wei, W. et al. (2010) Mol. Immunol. 47:2475.
  10. Sung, E-S. et al. (2009) Mol. Cancer Ther. 8:2276.
  11. Mom, C.H. et al. (2009) Clin. Cancer Res. 15:5584.
  12. MacFarlane, M. et al. (2005) Cell Death Differ. 12:773.
  13. Kurbanov, B.M. et al. (2005) J. Invest. Dermatol. 125:1010.
Long Name
TRAIL Receptor 1
Entrez Gene IDs
8797 (Human)
Alternate Names
APO2; CD261 antigen; CD261; cytotoxic TRAIL receptor; Death receptor 4; DR4 TRAIL receptor 1; DR4; TNF-related apoptosis inducing ligand receptor 1; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAILR1; TRAIL-R1; TRAILR-1; TRAILR1MGC9365; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily, member 10a

Citations for Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

  1. Combination effect of equol and TRAIL against human cervical cancer cells.
    Authors: Kim E, Kim A
    Anticancer Res, 2013;33(3):903-12.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion.
    Authors: Peppa, Dimitra, Gill, Upkar S, Reynolds, Gary, Easom, Nicholas, Pallett, Laura J, Schurich, Anna, Micco, Lorenzo, Nebbia, Gaia, Singh, Harsimra, Adams, David H, Kennedy, Patrick, Maini, Mala K
    J Exp Med, 2013;210(1):99-114.
    Species: Human
    Sample Types: Whole Cells
    Applications: Blocking
  3. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.
    Authors: Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J
    J. Clin. Invest., 2012;122(7):2369-83.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Authors: Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, Kirpichnikov MP
    Apoptosis, 2009;14(6):778-87.
    Species: N/A
    Sample Types: Protein
    Applications: Bioassay
  5. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
    Authors: He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS
    Oncogene, 2002;21(17):2623-33.
    Species: N/A
    Sample Types: N/A
    Applications: WB Ctrl

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein

There are currently no reviews for this product. Be the first to review Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein and earn rewards!

Have you used Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review